latest news releases from the newsroom
Generex Biotechnology Corp.
Generex Biotechnology to Commence Generex Oral-lyn Trial Involving Subjects With Impaired Glucose Tolerance
WORCESTER, Mass., Aug. 5, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has received approval from the ethics committee at University Campus Bio-Medico of Rome to conduct a Generex Oral-lyn trial with subjects diagnosed with or susceptible to developing Impaired Glucose Tolerance (IGT). The endpoint of the study is to determine if glucose levels will drop when subjects use Generex Oral-lyn, the Company's proprietary oral insulin spray product, with the Company's proprietary RapidMist(tm) drug delivery device.
Artificial Life, Inc.
Photo Release -- Artificial Life Announces New iPhone Game: VBotAttack
LOS ANGELES and HONG KONG, Aug. 5, 2008 (PRIME NEWSWIRE) -- Artificial Life, Inc., (OTCBB:ALIF) (www.artificial-life.com), a leading provider of mobile 3G+ technology, participation TV, games and business applications, announced today that the company will be releasing another title of its own branded V-series mobile game: VBotAttack. Developed exclusively for the iPhone and iPod(r) touch, VBotAttack will fully utilize the unique features of the mobile device, such as the accelerometer, touch-screen, 2D / 3D map landscapes and 2D / 3D vector graphics. The game is designed with intriguing logic and physics principles, challenging players' brainpower and problem-solving skills.
Barrier Therapeutics, Inc.
Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc.
PRINCETON, N.J., Aug. 5, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. ("Barrier Therapeutics") (Nasdaq:BTRX), a pharmaceutical company that develops and markets dermatology products, announced today that Stiefel Laboratories, Inc. ("Stiefel Laboratories"), through Stiefel Laboratories' wholly owned subsidiary, Bengal Acquisition Inc., completed its all cash tender offer for the outstanding shares of common stock of Barrier Therapeutics (Nasdaq:BTRX). The tender offer expired, as scheduled, at 12:00 midnight, New York City time, on Monday August 4, 2008.